PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
about
Advances in graft-versus-host disease biology and therapy.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethalityPD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.Advances in understanding the pathogenesis of graft-versus-host disease.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Inducible T-cell receptor expression in precursor T cells for leukemia control.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.The role of B7 family molecules in hematologic malignancyExpression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease.The B7 homologues and their receptors in hematologic malignancies.Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.Targeting Immune Checkpoints in Hematologic Malignancies.Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease.PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.Clinical Development of PD-1 Blockade in Hematologic Malignancies.
P2860
Q34031916-79E451E5-CA03-417A-871D-4868E251EAA7Q34648812-FC18C00B-A0FC-4ACD-8B73-AA65430712F2Q35634896-BD40E561-1F44-4F4D-83E4-EF15B7A6578AQ35921900-1A1F2982-F418-4FE5-8370-1A59683623E8Q35971439-EB5C3ACB-B63F-4526-904F-D730EEAB7395Q36130498-E880F021-C6C8-489D-AACA-EE9D6BB1CE5DQ36166038-47E08671-52F4-42FD-BC97-AA469772C141Q36522770-C4892B44-81E0-4D18-A407-26E80D689FD0Q36584814-573C2EE0-CCDB-4C00-9C0F-38AFD149F7AEQ37216330-465393CC-CD3F-446D-BC15-953F924B64EBQ37263177-13C615E1-BE01-41B1-BA68-1E2D5AA58A0EQ37479232-45F27A6F-02D4-4666-815E-1B6918D76DC9Q37988965-2E1B3746-14AF-46B1-A12D-8BC85E9F37A4Q38485334-0BF87249-D81B-410E-A75B-01EF2BC68A3FQ38891877-B8B00129-EFF4-4235-B1D5-762BAAF870B1Q38963420-EB5377FA-05A3-4049-A091-443B7767141EQ39116985-403174E6-5CB5-48A4-81F3-9576881644E0Q39161011-CF73E9F8-0AA2-4F32-B439-E83F78C10212Q39232385-2B6EAE0C-E947-4E9E-8865-FE900F42E3B8Q39802321-CD42AA57-57CA-4D8B-A842-B5254E7C82BDQ40216708-780A0ACD-EF45-4200-B0ED-31555B1FA2E0Q41897195-B76FC14A-106C-4CB6-B2BA-CB0E696B8133Q47681829-97B0D01F-FAB2-4BC9-8F7C-E002324EBCADQ47855599-992CD0F1-5BE8-4E90-B8C9-5F913476063CQ47952363-F7DB3A9A-8FA5-403A-BBAA-99B6C83F1C63Q48526801-308F76E8-3530-4D30-9D3E-4A499DAF6EA6
P2860
PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@ast
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@en
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@nl
type
label
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@ast
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@en
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@nl
prefLabel
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@ast
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@en
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@nl
P2093
P2860
P1433
P1476
PD-L1 blockade effectively res ...... eered allogeneic CD8+ T cells.
@en
P2093
Andrew Flatley
Christoph Klein
Dario A Vignali
Elmar Jaeckel
Jessica Herbst
Joerg Fruehauf
Karl Welte
Martin G Sauer
Martin Hapke
Matthias Hardtke-Wolenski
P2860
P304
P356
10.1182/BLOOD-2010-04-283119
P407
P577
2010-11-09T00:00:00Z